AFIRE Study: Atrial Fibrillation and Ischemic events with Rivaroxaban in patiEnts with stable coronary artery disease Study

Trial Profile

AFIRE Study: Atrial Fibrillation and Ischemic events with Rivaroxaban in patiEnts with stable coronary artery disease Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel; Prasugrel
  • Indications Atrial fibrillation; Ischaemia; Stroke; Thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AFIRE Study
  • Most Recent Events

    • 05 Dec 2017 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Dec 2015).According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Dec 2015).
    • 26 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top